Seeking Alpha

More on Valeant Pharma Q4: Bausch + Lomb lifts earnings

  • Valeant Pharma (VRX) swings to a net profit of $123.8M from a loss of $89.1M a year earlier, with earnings boosted by the acquisition of Bausch + Lomb.
  • The latest results include charges of $128M mainly related to the acquisition of Bausch + Lomb.
  • Same-store organic product sales +6%.
  • Valeant reaffirms 2014 guidance for EPS of $8.25-8.75 - not including the acquisition of PreCision Dermatology - revenue of $8.2-8.6B, and adjusted cash flow from operations of $2.4-2.6B.
  • Valeant expects to raise its outlook once it has closed the PreCision deal. (PR)
  • Previous
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector